< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 8 sources · 13 days · First seen · Last updated

FDA review of testosterone use in menopausal women

Overview

The U.S. Food and Drug Administration (FDA) held a public workshop in September 2026 to address the rising off-label use of testosterone therapy among menopausal women. While there are currently no FDA-approved testosterone formulations specifically for women in the United States, off-label prescriptions nearly tripled between 2016 and 2025.

Medical experts at the workshop noted that while the strongest scientific evidence supports testosterone use for treating hypoactive sexual desire disorder (HSDD), its efficacy for broader symptoms—such as mood, memory, muscle mass, and fatigue—remains unproven and requires further study. Clinicians currently often rely on formulations designed for men or compounding pharmacies to treat these symptoms.

Data from the longevity platform Hone Health, involving 1,220 women, indicated that users reported improvements across 18 different symptoms, with the most significant gains reported in sexual health, energy, stamina, and muscle mass. However, specialists emphasized that long-term safety and the clinical challenges of measuring lower testosterone concentrations in women remain key concerns.

Entities

Natalie Kunsman · Food and Drug Administration · The Menopause Society · Hone Health · International Society for the Study of Women’s Sexual Health

Claims

What the coverage asserts, and how many sources carry each claim.

Timeline

  1. [HEALTH] 5 sources
    FDA holds first workshop on testosterone use in menopausal women

    The FDA held its first workshop on testosterone use in menopausal women. While not FDA-approved for women, an analysis of 1,220 patients showed improvements in sexual desire, energy, and muscle mass.

  2. [HEALTH] 3 sources
    FDA examines testosterone use for menopausal women

    The FDA held a workshop to discuss the rising off-label use of testosterone for menopausal women, noting a lack of approved formulations and uncertainty regarding long-term safety for non-HSDD symptoms.

Sources

americafirstreport.com · formosadeportiva.com.ar · gq-magazine.co.uk · hcnews.com · keyt.com · kion546.com · krdo.com · kvia.com